Factors associated with prolonged viral shedding in patients with avian influenza a(H7N9) virus infection

Journal of Infectious Diseases

Volumn 217, Issue 11, 2018, Pages 1708-1717

  Wang, Yeming ^a,b,c   Guo, Qiang ^e   Yan, Zheng ^h   Zhou, Daming ⁱ   Zhang, Wei ^j   Zhou, Shujun ^e   Li, Yu Ping ^k   Yuan, Jing ^l   Uyeki, Timothy M ^as   Shen, Xinghua ^f   Wu, Wenjuan ^m   Zhao, Hui ⁿ   Wu, Yun Fu ^g   Shang, Jia ^r   He, Zhengguang ^s   Yang, Yi ^t   Zhao, Hongsheng ^u   Hong, Yongqing ^v   Zhang, Zehua ^o   Wu, Min ^w   Wei, Tiemin ^x   Deng, Xilong ^z   Deng, Yijun ^aa   Cai, Li hua ^ab   Lu, Weihua ^ac   Shu, Hongmei ^ad   Zhang, Lin ^p   Luo, Hong ^ae   Zhou, Ying ^af   Weng, Heng ^ag   Song, Keyi ^ah   Yao, Li ^q   Jiang, Mingguang ^ai   Zhao, Boliang ^aj   Chi, Ruibin ^ak   Guo, Boqi ^al   Fu, Lin ^am   Yu, Long ^an   Min, Haiyan ^ao   Chen, Pu ^k   Chen, Shuifang ^ap   Hong, Liang ^k   Mao, Wei ^ar   Huang, Xiaoping ^aq   Gu, Lijun ^y   Li, Hui ^b,c   Wang, Chen ^b,c,d   Cao, Bin ^b,c   more..

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d PEKING UNION MEDICAL COLLEGE   (China)

^e SOOCHOW UNIVERSITY   (China)

^f The Affiliated Infectious Diseases Hospital of Soochow University   (China)

^g SUZHOU MUNICIPAL HOSPITAL   (China)

^h WUXI PEOPLE'S HOSPITAL   (China)

ⁱ TAIZHOU PEOPLE S HOSPITAL   (China)

^j NANCHANG UNIVERSITY   (China)

^k WENZHOU MEDICAL UNIVERSITY   (China)

^l SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

^m Wuhan Medical Treatment Center   (China)

ⁿ ANHUI MEDICAL UNIVERSITY   (China)

^o Anhui No 2 Province People s Hospital   (China)

^p Department of Interventional Radiology   (China)

^q Intensive Care Unit   (China)

^r HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^s SUINING CENTRAL HOSPITAL   (China)

^t SOUTHEAST UNIVERSITY   (China)

^u NANTONG UNIVERSITY   (China)

^v NANJING MEDICAL UNIVERSITY   (China)

^w Department of Neurosurgery   (China)

^x LISHUI CENTRAL HOSPITAL   (China)

^y Suichang County People s Hospital   (China)

^z Guangzhou Number 8 People Hospital   (China)

^aa Yancheng First Peoples Hospital   (China)

^ab DONGGUAN PEOPLE'S HOSPITAL   (China)

^ac WANNAN MEDICAL COLLEGE   (China)

^ad Anqing Petrochemical Company   (China)

^ae CENTRAL SOUTH UNIVERSITY   (China)

^af CHINA MEDICAL UNIVERSITY   (China)

^ag Fuzhou Pulmonary Hospital   (China)

^ah Department of Spinal Surgery   (China)

^ai General Hospital of Wanbei Coal Electric Group   (China)

^aj Zhaoqing First People s Hospital   (China)

^ak Xiaolan Peoples' Hospital of Zhongshan   (China)

^al Putian Municipal Hospital   (China)

^am First People s Hospital of Xiangtan City   (China)

^an Department of Infectious Diseases Lu an People s Hospital   (China)

^ao Yunnan Provincial Hospital Infectious Disease   (China)

^ap Beilun District People s Hospital   (China)

^aq NINGBO FIRST HOSPITAL   (China)

^ar HUZHOU CENTRAL HOSPITAL   (China)

^as NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

more..

Author keywords

Antiviral drug; Avian influenza A(H7N9); Corticosteroid; Human; Neuraminidase inhibitors; Oseltamivir; Risk factor; Viral shedding

Indexed keywords

CORTICOSTEROID; OSELTAMIVIR; PERAMIVIR; RIBAVIRIN; SIALIDASE INHIBITOR; VIRUS RNA; ZANAMIVIR; ANTIVIRUS AGENT;

ADULT; AGED; ARTICLE; AVIAN INFLUENZA; AVIAN INFLUENZA (H7N9); CAUSE OF DEATH; CHINA; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DISEASE DURATION; DOSE RESPONSE; FEMALE; HAZARD RATIO; HOSPITAL MORTALITY; HOSPITAL PATIENT; HUMAN; HUMAN TISSUE; INFLUENZA A VIRUS (H7N9); MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; ONSET AGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL TIME; SURVIVOR; THERAPY DELAY; TIME; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRUS SHEDDING; ANIMAL; BIRD; CLINICAL TRIAL; DRUG EFFECT; INFLUENZA; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; VIROLOGY;

AGED; ANIMALS; ANTIVIRAL AGENTS; BIRDS; CHINA; FEMALE; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; RETROSPECTIVE STUDIES; VIRUS SHEDDING;

EID: 85052022138     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiy115     Document Type: Article

References (39)

1. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368:1888–97.
2. Wang X, Jiang H, Wu P, et al. Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013–17: an epidemiological study of laboratory-confirmed case series. Lancet Infect Dis 2017; 17:822–32.
3. Zhou L, Ren R, Yang L, et al. Sudden increase in human infection with avian influenza A(H7N9) virus in China, September-December 2016. Western Pac Surveill Response J 2017; 8:6–14.
4. Kile JC, Ren R, Liu L, et al. Update: increase in human infections with novel Asian lineage avian influenza A(H7N9) viruses during the fifth epidemic - China, October 1, 2016-August 7, 2017. MMWR Morb Mortal Wkly Rep 2017; 66:928–32.
5. Kang M, Lau EHY, Guan W, et al. Epidemiology of human infections with highly pathogenic avian influenza A(H7N9) virus in Guangdong, 2016 to 2017. Euro Surveill 2017; 22. doi: 10.2807/1560-7917.ES.2017.22.27.30568.
6. Zhou L, Tan Y, Kang M, et al. Preliminary epidemiology of human infections with highly pathogenic avian influenza A(H7N9) virus, China, 2017. Emerg Infect Dis 2017; 23:1355–9.
7. Uyeki TM, Katz JM, Jernigan DB. Novel influenza A viruses and pandemic threats. Lancet 2017; 389:2172–4.
8. Short KR, Kroeze EJBV, Fouchier RAM, Kuiken T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis 2014; 14:57–69.
9. Herold S, Becker C, Ridge KM, Budinger GR. Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur Respir J 2015; 45:1463–78.
10. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492–500.
11. McGeer A, Green KA, Plevneshi A, et al.; Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568–75.
12. Kumar D, Michaels MG, Morris MI, et al.; American Society of Transplantation H1N1 Collaborative Study Group. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10:521–6.
13. Yu H, Liao Q, Yuan Y, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ 2010; 341:c4779.
14. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55:1198–204.
15. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009–2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis 2013; 207:553–63.
16. Muthuri SG, Venkatesan S, Myles PR, et al.; PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395–404.
17. Chan PK, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis 2012; 206:1359–66.
18. Fielding JE, Kelly HA, Mercer GN, Glass K. Systematic review of influenza A(H1N1)pdm09 virus shedding: duration is affected by severity, but not age. Influenza Other Respir Viruses 2014; 8:142–50.
19. Zheng S, Wang Y, Yu F, et al. Benefit of early initiation of neuraminidase inhibitor treatment to hospitalized patients with avian influenza A (H7N9) virus. Clin Infect Dis 2017. doi: 10.1093/cid/cix930.
20. Cao B, Gao H, Zhou B, et al. Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia. Crit Care Med 2016; 44:e318–28.
21. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368:2277–85.
22. Tang BM, Craig JC, Eslick GD, Seppelt I, McLean AS. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med 2009; 37:1594–603.
23. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with the middle east respiratory syndrome. Am J Respir Crit Care Med 2017. doi: 10.1164/rccm.201706-1172OC.
24. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203–7.
25. Gu J, Xie Z, Gao Z, et al. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet 2007; 370:1137–45.
26. Hui DS, Lee N, Chan PK, Beigel JH. The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Res 2018; 150:202–16.
27. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 2004; 31:304–9.
28. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381:2273–9.
29. Ke C, Mok CKP, Zhu W, et al. Human infection with highly pathogenic avian influenza A(H7N9) virus, China. Emerg Infect Dis 2017; 23:1332–40.
30. Duval X, van der Werf S, Blanchon T, et al.; Bivir Study Group. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010; 7:e1000362.
31. South East Asia Infectious Disease Clinical Research N. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ 2013; 346:f3039.
32. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J Infect Dis 2010; 202:1154–60.
33. Yang SG, Cao B, Liang LR, et al.; National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS One 2012; 7:e29652.
34. Lee N, Hui DS, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. Clin Infect Dis 2013; 57:1511–9.
35. Widmer N, Meylan P, Ivanyuk A, Aouri M, Decosterd LA, Buclin T. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacody-namic characteristics. Clin Pharmacokinet 2010; 49:741–65.
36. Bantia S, Parker CD, Ananth SL, et al. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother 2001; 45:1162–7.
37. Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 2010; 65(Suppl 2):ii5–10.
38. Zhang Y, Gao H, Liang W, et al. Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study. BMC Infect Dis 2016; 16:76.
39. Dunning J, Baillie JK, Cao B, Hayden FG; International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Antiviral combinations for severe influenza. Lancet Infect Dis 2014; 14:1259–70.